Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Spruss

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Journal of Cancer Research and Clinical Oncology|January 1, 1992
Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activityG Bernhardt, H Reile, H Birnböck, et al.
Cancer Letters|December 5, 1998
Quantitation of hyaluronidases by the Morgan-Elson reaction: comparison of the enzyme activities in the plasma of tumor patients and healthy volunteersI Muckenschnabel, G Bernhardt, T Spruss, et al.
Oncogene|December 19, 2006
Functional implication of BMP4 expression on angiogenesis in malignant melanomaT Rothhammer, F Bataille, T Spruss, et al.
Oncogene|October 24, 2017
Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibitionP Dietrich, S Kuphal, T Spruss, et al.
Archiv Der Pharmazie|July 1, 1991
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part IV: Biological evaluation--in vivo studies on the P 388 leukemiaH Reile, T Spruss, G Bernhardt, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivoK Beckenlehner, S Bannke, T Spruss, et al.
Journal of Virology|January 9, 1999
Transforming potential of the adenovirus type 5 E4orf3 proteinM Nevels, B Täuber, E Kremmer, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancerT Spruss, S Schertl, M R Schneider, et al.
Virchows Archiv. B, Cell Pathology Including Molecular Pathology|January 1, 1987
Effect of estrophilic platinum complex on the mouse uterusW Amselgruber, F Sinowatz, T Spruss, et al.
Archiv Der Pharmazie|February 1, 1991
Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: SynthesisR Müller, E Schickaneder, M Jennerwein, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Journal of Cancer Research and Clinical Oncology|January 1, 1992
Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activityG Bernhardt, H Reile, H Birnböck, et al.
Cancer Letters|December 5, 1998
Quantitation of hyaluronidases by the Morgan-Elson reaction: comparison of the enzyme activities in the plasma of tumor patients and healthy volunteersI Muckenschnabel, G Bernhardt, T Spruss, et al.
Oncogene|December 19, 2006
Functional implication of BMP4 expression on angiogenesis in malignant melanomaT Rothhammer, F Bataille, T Spruss, et al.
Oncogene|October 24, 2017
Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibitionP Dietrich, S Kuphal, T Spruss, et al.
Archiv Der Pharmazie|July 1, 1991
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part IV: Biological evaluation--in vivo studies on the P 388 leukemiaH Reile, T Spruss, G Bernhardt, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivoK Beckenlehner, S Bannke, T Spruss, et al.
Journal of Virology|January 9, 1999
Transforming potential of the adenovirus type 5 E4orf3 proteinM Nevels, B Täuber, E Kremmer, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancerT Spruss, S Schertl, M R Schneider, et al.
Virchows Archiv. B, Cell Pathology Including Molecular Pathology|January 1, 1987
Effect of estrophilic platinum complex on the mouse uterusW Amselgruber, F Sinowatz, T Spruss, et al.
Archiv Der Pharmazie|February 1, 1991
Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: SynthesisR Müller, E Schickaneder, M Jennerwein, et al.
Pageof 5